Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 HKD | -2.80% | -0.71% | -4.79% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.79% | 180M | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-12.32% | 33.03B | |
+54.12% | 24.68B | |
-17.39% | 15.12B | |
-9.14% | 12.81B | |
-10.48% | 11.79B | |
-42.45% | 11.64B | |
+7.04% | 8.9B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Unit Completes Patient Enrollment for Phase 2 Trial for Biliary Cholangitis Drug; Shares Rise 8%